研究发现,像Ozempic这样的减重药物会降低阿尔茨海默氏症的风险,但可能会增加关节炎和GI问题。 Study finds weight-loss drugs like Ozempic reduce Alzheimer's risk but may increase arthritis and GI issues.

最近对诸如Ozempic和Wegovy(GLP-1受体激动剂)等重量损失药物进行的一项研究显示,这些药物对健康有各种影响。 A recent study on weight-loss drugs like Ozempic and Wegovy, which are GLP-1 receptor agonists, suggests they have various health impacts. 这些药物用于治疗肥胖症和2型糖尿病,降低心脏病、肾病和神经疾病的风险,包括阿尔茨海默氏病风险降低12%。 The drugs, used to treat obesity and type 2 diabetes, reduce the risk of heart disease, kidney disease, and neurological disorders, including a 12% decrease in Alzheimer's risk. 然而,它们也增加了肠胃问题、关节炎和胰腺炎的风险。 However, they also increase the risk of gastrointestinal issues, arthritis, and pancreatitis. 这项研究分析了200多万美国糖尿病患者,突显了这些药物的益处和潜在的新风险。 The study, which analyzed over two million US diabetes patients, highlights both benefits and potential new risks of these medications.